Through a combination of genomic, biochemical, and cell biological analyses, we have demonstrated that m6A RNA methylation levels and RNA methyltransferase METTL3 expression are highly increased in CRC patients with higher FDG uptake. The gene discussed is METTL3; the disease is colorectal carcinoma.